1855901261
Innovating Clinical Trials

Advertise on podcast: Innovating Clinical Trials

This podcast has
75 episodes
Language
English
Explicit
No
Date created
2025/11/25
Latest episode
2026/11/10
Average duration
19 min.
Release period
3 days

Description

Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.Ted Trafford - https://probitymedical.com/With 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 75+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.Liam Eves - https://www.theendpointpodcast.com/Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer.  Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building  and advising companies in the clinical trial space. Opinions expressed are those of the participants and not their employers. 

Unlock Innovating Clinical Trials podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Innovating Clinical Trials podcast


ICT Ep 2.46: Paul Ivsin on Deciding When to Fire Your Recruitment Vendor Before Patient One (Part 3/3)
2026/11/10
In the final part of this three-part conversation, Liam and Ted ask Paul Ivsin, Principal at First Patient In, a question that made everyone laugh: when should you fire a recruitment vendor? Paul's answer is that the decision belongs before the first patient is enrolled. Once a study is running, nobody agrees to change anything, so the only window is early. Agree a checkpoint, such as a hard look at 15% or 20% of target, and write down what "off track" means. Then treat it the way a trial treats an interim analysis: a planned moment to look at the data and make a go or no-go call on the operations. He admits the weakness too. Interim analyses often come back ambiguous, and so will this one. That leads to the theme of the episode: we run careful experiments on the drug and almost none on the enrollment. Paul uses pre-screeners as the example. Some have three questions, and he recently saw one with 21 that he couldn't finish himself. Which is better? After 25 years, he doesn't know, and says the honest answer is to put both versions on the same website, randomise, and count. When he has suggested this to larger pharma companies, nobody has liked it, because "we don't know" is hard to say out loud. Liam adds that no question count will ever be right for every patient, so segmenting by urgency and unmet need, even into eight rough buckets, beats pretending there is one answer. Ted closes with the big question: with all the tools we have now, are we getting better at recruitment or worse? Paul says both. The best digital programs are smarter and work better with sites than anything from ten years ago. But outreach has concentrated on Facebook, Instagram and Google, and anyone with a laptop and some overconfidence can now call themselves a recruitment company. He expects a reshuffle, because sites that understand what a screened patient is worth to them can run those ads themselves. Find Paul at firstpatientin.com and on the First Patient In on Substack.
ICT Ep 2.45: Paul Ivsin on the Text Reminder Every Dentist Sends and Some Sites Don't (Part 2/3)
2026/11/10
In Part 2 of this three-part conversation, Liam and Ted pick up with Paul Ivsin, Principal at First Patient In, at the point where most campaigns leak: the handoff between pre-screening and the site. It opens with an exercise the hosts ran on a number of central advertising campaigns. They took the pre-screening questions meant to qualify candidates and laid them against the protocol language. Every campaign had questions that either let the wrong patients through or turned the right ones away, and each had passed an ad agency and a sponsor review. Paul thinks this is getting worse. Turning a protocol criterion into a question a patient can answer always means choosing which errors you can live with, and some pre-screeners now look like they took under a minute to generate. From there the conversation turns to ownership. Liam has been reading CRO budgets with biotechs and keeps finding the same thing: the most senior recruitment person on the study is an associate director at around two hours a month, while the project manager and data manager have full seats at the table. Paul sees it from the vendor side. Some CROs still make money on change orders and have little reason to shorten a timeline. Many sponsors hand recruitment to a vendor and stop looking, so ask how enrollment is going overall, and someone starts digging through a spreadsheet. When a study is three months in and behind, the usual answer is "it'll catch up once more sites activate." Paul's point is that this is an answerable question: you have activation dates and patients in, so you have a rate. Ted raises no-shows, which he sees rising at sites. Paul's experience is that a persistent 20 to 30% of referrals never answer the phone once handed over, and the fixes that work are basic: send the text reminder every dentist sends, and hire someone for intake so study coordinators, who are often better with data than with people, aren't the ones phoning every referral.
ICT Ep 2.44: Paul Ivsin on the 80% Stat That Leads to a Missing Book (Part 1/3)
2026/11/10
In Part 1 of this three-part conversation, Liam and Ted sit down with Paul Ivsin, Principal at First Patient In, who has spent more than 20 years building enrollment programs with sponsors, sites and recruitment vendors. Paul studied philosophy, drifted into database work, and landed in recruitment through a client running radio and newspaper ads for a trial. The phones were ringing and leads were being faxed to sites, but nobody could prove a single call had turned into a patient. He was hired to build the tracking. Twenty-five years later, he says, the industry still struggles to connect recruitment activity to enrollment. That habit of asking "where did this number come from?" led him to the most quoted statistic in the industry: 80% of trials miss their enrollment timelines. The number has not moved in two decades, which made Paul wonder whether anyone was still measuring it. He followed the citations backwards and the trail ends at a source book from around 2000 that he has never been able to find. Worse, the question is broken anyway. Most studies have three timelines, the feasibility estimate, the CRO's bid and the date the CEO announced, so a trial can beat one and miss another. Paul's bigger worry is how the stat gets used: when everything is declared broken, any solution looks reasonable. The conversation then turns to what Paul's data shows about digital advertising. Ads built for retail are made to maximise clicks, and a trial needs the opposite: only the people who will qualify. When he has compared the best-performing ads by clicks with the ones that produced enrolled patients, the correlation has often been negative. Paul closes on where he would look first to improve any campaign: the handoff from pre-screening to the site. In a single campaign, with the same ads and the same pre-screener, he has seen one site consent 20% of its referrals while three others consented none.
ICT Ep 2.43: Robert Goldman on AI in Clinical Operations: Innovation or Marketing? (Part 3/3)
2026/11/06
In Part 3 of this three-part conversation, Liam and Ted wrap up their discussion with Robert Goldman, Vice President and Global Head of Clinical Operations at Contraline, on a question that lands in every ClinOps inbox: is “AI-powered” innovation or marketing? Robert explains why a dashboard from eight years ago isn’t new just because it has an AI label, how to test a vendor’s pitch, and why AI should support clinical judgment, not replace it. He also asks the question he puts to every AI vendor: if the hours saved are real, why aren’t drugs reaching patients faster? It’s the same demand for evidence Robert brings to feasibility estimates and site selection in Parts 1 and 2 of the series. Listen to all parts of the conversation to see how it runs from the first plan to the latest technology.
ICT Ep 2.42: Robert Goldman on Rethinking Feasibility (Part 2/3)
2026/11/05
In Part 2 of this three-part conversation, Liam and Ted continue their discussion with Robert Goldman, Vice President and Global Head of Clinical Operations at Contraline, to talk about why feasibility so often fails to predict what happens next.  Robert explains why historical benchmarks mean little for a study that has never been done, and what he would use instead: measurable assumptions, early performance indicators, and intervention points agreed in advance. Ted raises the feasibility question he has never seen on a questionnaire, and Robert explains why sites are afraid to answer it honestly. They discuss why sponsors budget for backup sites, why the fastest responders aren’t always the best, and how sponsors can build real relationships with sites before the selection process begins. Join us in Part 3 of the conversation as Robert gives his take on AI in clinical operations.
ICT Ep 2.41: Robert Goldman on "Optimism Is Not an Enrollment Plan" (Part 1/3)
2026/11/04
In Part 1 of this three-part conversation, Liam and Ted sit down with Robert Goldman, Vice President and Global Head of Clinical Operations at Contraline, who brings nearly 20 years of clinical research experience spanning CRO roles and sponsor-side clinical operations, to talk about why the industry rewards optimism in planning and demands realism in execution. Robert shares how a detour through Caribbean medical school led him into clinical research by accident, and what he has learned about how lean biotech teams succeed: knowing what to build, what to outsource, and what good looks like. Together they look at why feasibility estimates stay unrealistic when everyone is incentivized to present the best case, and why optimism is not an enrollment plan. Robert leaves listeners with the question he would ask instead of “how many patients can you enroll?”: show me the evidence for your estimate, and tell me what happens when you’re wrong.
ICT Ep 2.40: Duncan Shaw on the AI Translation Trap: Why the Human “Last Mile” Still Matters When the Stakes Are High (Part 3/3)
2026/10/29
In Part 3 of this three-part conversation, Liam and Ted wrap up their discussion with Duncan, President at DTS Language Services about AI, risk mitigation, and the human factors that are hard to capture in clinical trial translation. Duncan calls translation the “last mile” of clinical trials, where small details can decide whether a site activates or a patient stays in a study. He explains why AI has a place when millions of words are on tight timelines, but argues that low-volume, high-risk clinical content is a very different proposition. He compares AI translation to an autopilot where the human is only brought in after something goes wrong, and describes how translators are spending 80% to 90% of the usual effort correcting AI output while being asked to accept much lower prices.  And just when it gets serious, Duncan closes with a story about what happened when he translated a stack of Chinese tattoos. Spoiler: most of it was gibberish!
ICT Ep 2.39: Duncan Shaw on the Translation “Quilt Factor”: How Inconsistency Can Erode Patient Trust and Derail Trial Operations (Part 2/3)
2026/10/28
In Part 2 of this three-part conversation, Liam and Ted continue their discussion with Duncan, President at DTS Language Services about patient trust, consistency, and the operational realities of translating clinical trial content.  Duncan explains how small issues, from inconsistent terminology to differences in date formats, can undermine a patient’s confidence in a study and even lead to missed visits. Trust comes from consistency, fewer handoffs, and an approach that fits the purpose of the content, and describes the “quilt factor” that builds up when previous translations, multiple CROs, and competing terminology databases pile on top of each other.  The conversation ends on a question every sponsor should ask before translation begins: what does success actually look like?
ICT Ep 2.38: Duncan Shaw on the Hidden Risks of Clinical Trial Translation: What Happens With One Wrong Word (Part 1/3)
2026/10/27
In Part 1 of this three-part conversation, Liam and Ted sit down with Duncan, President at DTS Language Services, to talk about the good, the bad, and the ugly of clinical trial translation. Drawing on experience in both pharmaceutical and language services, Duncan explains why translation is far more than converting words from one language to another, and why a mistranslation in a clinical study isn’t just a typo but a potential risk to a patient, a trial, or a regulatory submission. Duncan explains why the real work of translation starts before the translation itself: understanding who is reading the content, their language, reading level, context, fears, and emotions, and making sure the final version is both linguistically trusted and faithful to the approved source. He argues that translators have to resist the temptation to “improve” content. Liam connects this to a problem he's seen: the constant addition of complexity, particularly in consent forms. This episode is a candid look at the hidden complexity behind clinical trial translation and the role it plays in patient trust, compliance, and study execution.
ICT Ep 2.37: "You Lose a Patient You Didn't Even Know You Lost" Why No One Owns Recruitment
2026/10/26
In this episode, Ted introduces the “ENROLL Corporation” (Everyone Needed for Recruitment Optimization Leadership and Logistics) an imaginary joint venture owned by the sponsor, the CRO, every site, and every vendor. He explains why most recruitment providers solve one small piece of the problem, much like a wildlife photographer so focused through a 500mm lens that an animal wanders past unnoticed.  Liam adds a river analogy about who “eats their own cooking,” and together they look at the 80-plus factors that affect recruitment, the holes in the enrollment funnel that nobody measures, and how adding complexity to a protocol can quietly cost months.
ICT Ep 2.36: Robin Piazza on ICH E6 R3 and the New Rules for Safety Oversight (Part 2/2)
2026/10/23
In Part 2, Robin Piazza, Liam and Ted get specific about what good safety oversight actually looks like in practice,  and what sponsors are getting wrong under the shift from FDA 2024 guidance to the stricter ICH E6 R3 standard.  We explore: - FDA 2024 guidance vs. ICH E6 R3: why global studies need one uniform plan - Why a DMC charter is a “how the DMC will operate," not evidence, and is what inspectors actually want to see, and whether the charter was followed. - The hidden conflict when the same experienced DMC member sits on multiple competing trials What a safety oversight committee looks like when it’s “firing on all cylinders." Robin also digs into a problem many sponsors don’t see coming: experienced DMC members who sit on multiple competing trials and intelligence bias the conflicts this creates. This is the practical half of the conversation, moving from why to how, with guidance on getting your safety oversight set up and ready before an inspector asks to see it.
ICT Ep 2.35: Robin Piazza on the Safety Oversight Gap No One's Training For (Part 1/2)
2026/10/22
Robin Piazza reached out to us directly with this topic suggestion, and we’re glad she did. In Part 1 of this two-part conversation, Liam and Ted sit down with Robin, Founder of Sapiens GC, who spent over 20 years building and running the industry’s first commercial data monitoring committee service before going independent. She breaks down what a data safety monitoring committee actually does, where sponsors, CROs, and vendors each fall short, and why having one independent, unblinded party in the room can make or break a study’s compliance.  We explore: - Why safety oversight responsibility has shifted onto sponsors and why there’s still no playbook for it - What Robin learned from years of “rescue projects” where another vendor’s DMC setup had already gone wrong - Why an independent, unblinded party in the room changes what a sponsor can actually prove during an inspection If you’ve ever wondered who’s really accountable when something goes wrong in a trial, this episode starts answering that.
ICT Ep 2.34: Study Startup Delays Are a Symptom: What Happens When You Stop and Listen
2026/10/21
In this episode, Liam and Ted ask a simple “what if”, what if the industry took the time to really listen?  Ted starts with a study startup delay that looks like a tooling problem but turns out to be a relationship problem. While Liam shares what happened when he pulled a frontline team member into a leadership meeting and found a patient-flow blocker that had backed up a 120-patient-a-day site for days. They talk about why most trial meetings leave no room for problem-solving or relationship-building, why no one truly owns enrollment, and why the simplest rule for building connections is to be helpful, be nice, and go first.  The takeaway is a short one: call somebody today.
ICT Ep 2.33: Steve Wimmer on the Button That Almost Killed a Recruitment Campaign (Part 3/3)
2026/10/08
Each episode in this series has built toward this one: what does all of this look like from the other side of the table?  In the final part of this series, the Steve Wimmer shares his experince participating in several clinical trials himself, including one he screen-failed out of, and shares what that experience actually taught him about consent, communication, and being left in the dark. Liam and Ted add their own stories of trying to get into a trial as ordinary, motivated patients and being met with silence from both the sponsor and the site.   The conversation closes with one of the most useful stories in the whole series: a call-to-action button on a campaign targeting patients 85 and older that tanked conversion until someone pointed out there was, quite literally, no visible button. Steve leaves listeners with a challenge to the industry's call-and-give-up mentality: with the automation available today, there's no reason to give up on an interested patient just because they didn't pick up the phone the first, second, or fifth time.
ICT Ep 2.32: Steve Wimmer on Why Recruitment Campaigns Fall Apart at the Site (Part 2/3)
2026/10/07
Part 1 was about why storytelling matters, part 2 is about how to actually operationalize it and Steve Wimmer brings a framework that reframes the entire recruitment funnel. Every interaction a patient has, from the first ad to the first phone call, is either a trust deposit or a trust withdrawal. Miss that, and the best story in the world won't save a campaign that confuses people the moment they land on a website.  Steve Wimmer, Liam Eves, and Ted Trafford move from why storytelling matters to how to actually build a recruitment engine around it. Steve introduces a framework that's worth stealing. He explains why building hundreds of interchangeable creative assets beats chasing one "perfect" ad, and why the hardest part of recruitment isn't generating interest, it's what happens after a lead lands at a site with no clear owner.  The episode also includes one of the most concrete stories in the series: an eligibility question that should have disqualified around 20% of a patient population but was disqualifying far more and how Steve's team tackled it and watched the numbers snap back to where they should have been. It's a small story with a big point, most recruitment problems aren't unsolvable, they're just approached differently.

Podcast reviews

Read Innovating Clinical Trials podcast reviews


0 out of 5
0 reviews

Podcast sponsorship advertising

Start advertising on Innovating Clinical Trials relevant audience podcasts


What do you want to promote?